A reference guide to how research peptides are made
How synthetic peptides are made.
Most research peptides are built by chemistry, one amino acid at a time, then cut free, purified and freeze-dried. Each stage leaves its mark on the powder: the impurities an HPLC run can see, the counterions that add weight, and the terminal groups that change charge and mass. This guide follows a peptide from sequence to certificate, so that a laboratory preparing a stock solution or an analytical method knows what the material contains and why.
For laboratory research use only. Not for human or veterinary use.
In this guide
How is a synthetic peptide made?
A synthetic peptide is built by chemistry, one amino acid at a time, on insoluble resin beads.
The method is solid-phase peptide synthesis, or SPPS. R. B. Merrifield introduced it in 1963, and most peptides are now manufactured this way. Its modern form, Fmoc SPPS, produces the majority of synthetic peptides; the older Boc method is now used mainly for specialist work.
Four stages turn a sequence into a vial of powder:
- Assembly: the chain is built on the resin, one residue after another.
- Cleavage: an acid mixture releases the finished chain and removes its protecting groups.
- Purification: preparative HPLC separates the target from the chains that went wrong.
- Freeze-drying: the purified fractions are dried to a powder.
Each stage explains something you will meet on a certificate or in a chromatogram, and the sections below take them in order. They describe how research peptides are generally made, not the process of any one manufacturer.
What happens in each synthesis cycle?
The first amino acid, the one that will sit at the C-terminus, is attached to the resin, usually cross-linked polystyrene. The chain then grows toward the N-terminus through the same short synthesis cycle, repeated once for every residue.
- Start: attach the first amino acid to resin
- After the loop: release, precipitate, purify and freeze-dry
- 01
Remove the temporary group
The amine at the end of the chain carries a temporary protecting group. In Fmoc chemistry a base removes it, typically piperidine, often at 20% in DMF. In the Boc method this step uses a moderate acid instead.
- 02
Wash
Because the chain is anchored to a solid, reagents and by-products are filtered and washed away. Nothing needs to be purified between steps.
- 03
Couple the next amino acid
The next amino acid arrives with its own amine protected and its side chain still blocked, so it can join only at the free end of the chain. In Fmoc/tBu chemistry the side-chain groups survive every base step and come off only in the final acid step. Chemists call this pairing of temporary and permanent groups orthogonal.
- 04
Wash again
A second wash clears the excess reagent before the next residue is added.
- 05
Cap chains that did not react
Some procedures add an optional capping step that permanently blocks any chain end that failed to couple. A capped chain stops growing and ends up as a shorter, truncated sequence.
The steps repeat until the last residue is in place: two chemical steps, deprotection and coupling, for every residue in the sequence.
Why does the yield fall as a chain gets longer?
No deprotection or coupling is perfectly complete, and the small shortfalls multiply.
A chain of 70 residues needs about 140 deprotection and coupling steps. Even if every step reaches 99% efficiency, only about 24% of the chains are full length at the end, in theory. The rest are incomplete chains that purification has to remove.
Length is not the only limit. Publications often give about 50 residues as the length that can be made routinely, but a review of the method calls that figure meaningless in practice: many much shorter sequences are extremely problematic. The main obstacle is aggregation, where growing chains associate with one another on the resin. Chemists call these difficult sequences.
- 10 residues · 20 steps
- 54.4% full-length chains at 97% per step; 81.8% at 99%; 90.5% at 99.5%
- 30 residues · 60 steps
- 16.1% full-length chains at 97% per step; 54.7% at 99%; 74.0% at 99.5%
- 70 residues · 140 steps
- 1.4% full-length chains at 97% per step; 24% at 99%; 50% at 99.5%
Theoretical fraction of full-length chains if every deprotection and coupling reaches the stated efficiency, at two steps per residue. The 70-residue row is a published supplier calculation; the shorter rows apply the same arithmetic. Real syntheses vary with the sequence.
What is cleavage, and why is TFA in the powder?
Cleavage is the last chemical step. One acid treatment releases the chain from the resin and removes the side-chain protecting groups together.
Fmoc synthesis uses trifluoroacetic acid, usually shortened to TFA, for this step. It is less hazardous than the hydrogen fluoride that the older Boc method needs, which is one reason Fmoc became the preferred method.
The cleavage mixture is mostly TFA, with a few percent of scavengers such as water, a silane or a thiol. Removing the protecting groups releases reactive fragments, and sensitive residues can form adducts with them; the scavengers keep those side reactions to a minimum.
The crude peptide is then precipitated out of the acid with cold ether.
TFA is a strong acid, with a pKa of 0.52, and it is volatile. Free TFA leaves when the peptide is later freeze-dried. TFA bound to the peptide’s positive charges stays behind as a counterion, which is where the counterion section below picks up.
What does preparative HPLC remove, and what can it miss?
The crude peptide is a mixture of the full-length target and every chain that went wrong along the way. Reversed-phase HPLC is the routine way to separate them, and a consensus specification for peptide standards names preparative reversed-phase HPLC as the purification method.
The column is usually silica bonded with C18 chains, the mobile phase is water and acetonitrile, and about 0.1% (v/v) of an acid such as TFA is added. The separation matters because impurities can lead an early laboratory study to a wrong conclusion.
A residue is missing
A deprotection or coupling step was incomplete, and the chain carried on growing without that residue. A deletion is lighter than the target by the mass of what is missing, so mass spectrometry usually identifies it even when the chromatography barely separates it.
The chain stopped early
A chain that stopped growing, for example because a failed coupling was capped, is shorter than the target. Tandem mass spectrometry of a minor peak can show this kind of premature termination.
A protecting group stayed on
A side-chain protecting group that survived cleavage leaves a peptide–protection adduct. Fragments released during cleavage can also form adducts with sensitive residues.
Other by-products of synthesis
Deprotection can racemize residues and give diastereomers. Excess reagent can insert an extra residue. Side chains can oxidize, and chains can pair into dimers and larger oligomers.
What purification cannot remove
An impurity that elutes with the target stays inside the main peak, and so inside the purity figure. One side reaction, aspartimide formation, can give nine different by-products, some of which co-elute with the target.
Degradation after manufacture adds its own products, such as pyroglutamate and succinimide forms; the stability guide covers those. The teaching guide covers TFA and formic acid in analytical HPLC.
Why are purified peptides usually TFA salts, and how is the salt changed?
TFA is in the purification mobile phase, so a peptide purified by reversed-phase HPLC usually comes out as a trifluoroacetate salt.
Which groups carry a counterion, and how much weight it adds to a powder, is worked through in the net-content guide. This section covers how the salt is changed.
There are three common routes to exchange TFA:
- Repeated dissolution in dilute hydrochloric acid, each time followed by freeze-drying, which gives the chloride salt.
- An ion-exchange resin carrying the wanted counterion.
- A switch of the mobile-phase acid during purification, for example to acetic acid, which gives the acetate salt.
The hydrochloric-acid route is simple but limited. It must be repeated several times, reported exchange reaches up to about 98% rather than all of it, and the strongly acidic conditions can degrade the peptide. It also works only with acids stronger than TFA, so it cannot produce an acetate salt. Exchange to acetate uses distinctly milder conditions.
USP 〈503〉 and 〈503.1〉 are pharmacopoeial procedures for measuring acetate and trifluoroacetate in peptides.
Residual trifluoroacetate can interfere with some cell-based methods, which is one reason laboratories check the salt form before such work.
What do N-terminal acetylation and C-terminal amidation change?
A peptide’s ends can be left free or modified. Each modification removes a terminal charge and changes the mass, and both matter when the peptide is dissolved or analyzed.
The free amine is capped
- Charge: the positive charge of the free N-terminus is removed.
- Mass: about 42 Da heavier than the free-amine chain.
- How it is made: the finished chain can be acetylated while it is still on the resin, before cleavage.
- Counterions: an acetylated N-terminus carries no counterion, so the salt holds one fewer.
The free acid becomes an amide
- Charge: the negative charge of the free C-terminus is removed.
- Mass: about 1 Da lighter than the free acid (0.98 Da).
- How it is made: by the resin chosen at the start. Amide-forming resins such as Rink, PAL and MBHA release amides; acid resins such as Wang release free acids.
Work from the modified sequence
- Solubility: with fewer terminal charges, both modifications often make a peptide less soluble than its unmodified form.
- First solvent: the terminal groups count when net charge is used to choose a first solvent.
- Identity by MS: the expected mass has to be calculated for the modified sequence.
- A shared 0.98 Da: the free-acid form of an amidated peptide is 0.98 Da heavier, the same shift as deamidation. Mass alone cannot tell a lost C-terminal amide from a deamidated asparagine or glutamine; fragmentation data or retention can.
What does “API” mean, and why does GPC not use the term?
API stands for active pharmaceutical ingredient. It is a drug-manufacturing term, and it describes a material’s intended place in drug production, not how pure the material is.
ICH Q7, the international guide to good manufacturing practice (GMP) for APIs, defines one as “Any substance or mixture of substances intended to be used in the manufacture of a drug (medicinal) product and that, when used in the production of a drug, becomes an active ingredient of the drug product.” Canada’s Food and Drug Regulations frame the term the same way, around the fabrication of a pharmaceutical.
Both definitions turn on use in drug manufacture. Q7 then sets out how APIs are to be made: under good manufacturing practice and a system for managing quality, to help ensure that they meet the quality and purity they are represented to possess.
GPC offers its material for laboratory research only. It does not offer or supply it for clinical or diagnostic procedures, personal or household use, or incorporation into products intended for such uses, and it does not supply material qualified for regulated product release. GPC therefore does not use the term API for its material, or any grade name borrowed from drug manufacturing. It describes the material by measured values, such as those reported on a lot’s certificate.
How does a purified peptide become the powder in a vial?
The purified fractions are pooled and freeze-dried.
Freeze-drying removes the water and the volatile mobile-phase acid. Counterions bound to the peptide stay, and some water remains, so the powder is not all peptide.
Net peptide content, the share of a weighed sample that is peptide once water and counterions are excluded, is usually measured by amino acid analysis. The net-content guide shows how it combines with HPLC purity.
A certificate brings the stages of this page together: HPLC purity for what purification left behind, a mass spectrum for identity and, where a laboratory measured it, the net content. The COA guide reads one field by field.
Common questions about peptide synthesis.
How is solid-phase peptide synthesis done?
The C-terminal amino acid is attached to insoluble resin beads, and the chain grows toward the N-terminus by one residue per synthesis cycle: remove the temporary protecting group from the chain end, wash, couple the next protected amino acid and wash again. In the Fmoc method, which now produces most synthetic peptides, a base such as piperidine removes that temporary group, while the side-chain groups stay on until the final acid step.
How does HPLC purity differ from net peptide content?
HPLC purity is the main peak’s share of the detected peak area. Net peptide content is the share of the powder’s weight that is peptide, excluding water and counterions. A powder can show a high purity figure and still be one-fifth counterion and water. The net-content guide works through an example and explains why laboratories multiply the two rather than choose one.
Does the TFA salt matter in cell-based assays?
It can. Peptides purified by reversed-phase HPLC are usually TFA salts. In one study with cultured cells, trifluoroacetate at 10⁻⁸ to 10⁻⁷ M reduced cell numbers, and the authors advised converting peptides to a hydrochloride or equivalent salt before such work. Where a method is sensitive, laboratories use an acetate or chloride salt, or exchange the counterion first.
What are deletion and truncation impurities?
A deletion is missing one or more internal residues, because a deprotection or coupling step was incomplete and the chain carried on growing. A truncation stopped growing early, for example after an unreacted chain end was capped. Both are lighter than the target, so mass spectrometry usually identifies them. Preparative HPLC removes most of them, but not an impurity that co-elutes with the target.
What purity does a laboratory method need?
There is no single threshold; the requirement follows the measurement. A consensus specification for peptides used as mass-spectrometry calibrators asks for a main peak of more than 95% of the HPLC area, with net peptide content confirmed by amino acid analysis. The same authors accept a main peak of more than 50% for screening work, provided the target is the highest peak in the chromatogram. For quantitative work, purity alone is not enough: identity and net content have to be known as well.
Why does GPC not call its peptides APIs?
Because the term belongs to drug manufacturing. Under ICH Q7, an active pharmaceutical ingredient is a substance intended for the manufacture of a drug product. GPC offers its material for laboratory research only, and describes it by measured values, such as those on a lot’s certificate.